XSpray Pharma AB (XSPRAY.ST) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · Sweden · ISIN SE0009973563

Price
10.70 SEK
Market cap
507.36 m SEK
P/E (2025)
–
P/S (2025)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
-28.35 %
Return on assets (ROA)
-22.28 %

XSpray Pharma AB financials

Fiscal year20242025
Revenue0.00 SEK0.00 SEK
Gross profit-8.55 m SEK-5.58 m SEK
Operating income-283.24 m SEK-161.85 m SEK
EBIT-283.24 m SEK-161.85 m SEK
Net income-285.52 m SEK-171.44 m SEK
Diluted EPS – continuing operations-8.62 SEK-4.46 SEK

Full history since 2015, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About XSpray Pharma AB

Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the treatment of kidney cancer; and XS025, a amorphous non-crystalline cabozantinib for the treatment of renal cell carcinoma and other cancers. It has partnership agreements with EVERSANA for the commercialization of Dasynoc. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is headquartered in Solna, Sweden.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.